Open AccessDownregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion
Author(s) -
Chen Jintu,
Chen Canwei,
Lin Yongfa,
Su Yongfa,
Yu Xueping,
Jiang Yancheng,
Chen Zixuan,
Ke ShaoYing,
Lin ShaoZe,
Chen LiangJuan,
Zhang Zhishan,
Zhang Tao
Publication year - 2021
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.13173
Subject(s) - gene knockdown , downregulation and upregulation , cancer research , biology , cell growth , cell culture , metastasis , cell migration , microbiology and biotechnology , cancer , gene , biochemistry , genetics
This study aimed to evaluate the prognostic value and biological function of small ubiquitin‐like modifier 2 ( SUMO2 ) in hepatocellular carcinoma (HCC). SUMO2 expression in HCC tissues was markedly higher than that in normal liver tissues, and patients with high SUMO2 expression had significantly shorter median overall survival than those with low SUMO2 expression. Furthermore, SUMO2 expression was closely correlated with lymph node metastasis and vascular invasion and was a predictor of poor prognosis. The knockdown of SUMO2 in two HCC cell lines (SMMC‐7721 and Bel‐7404) dramatically suppressed their proliferation, migration and invasion. Western blot analysis showed that the downregulation of SUMO2 significantly reduced the expression of Ki‐67, matrix metalloproteinase‐9 (MMP‐9) and vascular endothelial growth factor (VEGF) in SMMC‐7721 and Bel‐7404 cells. Similarly, quantitative reverse transcription–PCR revealed consistently decreased expression of MMP‐9 and VEGF . Our data suggest that SUMO2 promotes proliferation, migration and invasion of HCC cells via mechanisms involving MMP‐9 and VEGF. Therefore, SUMO2 may be a prognostic factor and a promising therapeutic target for patients with HCC.